URB597 is a selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH). FAAH is responsible for the degradation of the endocannabinoid anandamide, and its inhibition by URB597 leads to increased levels of anandamide in the central nervous system and peripheral tissues.
This accumulation of anandamide activates cannabinoid receptors, resulting in potential therapeutic effects. Preclinical studies have demonstrated that URB597 exhibits antidepressant-like and analgesic properties, making it a promising candidate for the treatment of conditions such as social anxiety disorder and post-traumatic stress disorder (PTSD).
Additionally, URB597 has been shown to modulate neuroinflammation and improve memory in animal models, even in the presence of ethanol exposure.
The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
| Other Names | URB-597, URB 597 |
|---|---|
| IUPAC Name | [3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate |
| CAS | 546141-08-6 |
| Molecular Weight | 338.4 |
| Molecular Formula | C20H22N2O3 |
| SMILES | C1CCC(CC1)NC(=O)OC2=CC=CC(=C2)C3=CC(=CC=C3)C(=O)N |